// App-Quantinova.ai

: Cabozantinib in combination with atezolizumab in non-clear cell renal cell carcinoma: Extended follow-up results of cohort 10 of the COSMIC-021 study.

Researchers

Presenter

  • Bradley Alexander McGregor

Principal Investigators

  • Neeraj Agarwal

  • Cristina Suárez

  • Kai Tsao

  • William Kevin Kelly

  • Lance C. Pagliaro

  • Ulka N. Vaishampayan

  • Daniel Castellano

  • Yohann Loriot

  • Fiona Xu

  • Lana Andrianova

  • Ramu Sudhagoni

  • Toni K. Choueiri

  • Sumanta Monty Pal

Medical Centers

  • Thomas Jefferson University, Philadelphia, PA

  • Mayo Clinic, Rochester, MN

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

  • Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus,Barcelona,Spanien

  • Division of Hematology/Medical Oncology, The Mount Sinai Hospital, New York, NY

  • Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • City of Hope Comprehensive Cancer Center, Monrovia, CA

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • Spain

  • France

  • United States

Companies

  • Exelixis, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Clear cell renal carcinoma

  • non-clear cell renal carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Atezolizumab

  • Cabozantinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • NCT03170960

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved